JP2002506044A5 - - Google Patents

Download PDF

Info

Publication number
JP2002506044A5
JP2002506044A5 JP2000535362A JP2000535362A JP2002506044A5 JP 2002506044 A5 JP2002506044 A5 JP 2002506044A5 JP 2000535362 A JP2000535362 A JP 2000535362A JP 2000535362 A JP2000535362 A JP 2000535362A JP 2002506044 A5 JP2002506044 A5 JP 2002506044A5
Authority
JP
Japan
Prior art keywords
follistatin
functional fragment
disease
composition according
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000535362A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002506044A (ja
Filing date
Publication date
Priority claimed from US09/037,118 external-priority patent/US6004937A/en
Application filed filed Critical
Publication of JP2002506044A publication Critical patent/JP2002506044A/ja
Publication of JP2002506044A5 publication Critical patent/JP2002506044A5/ja
Withdrawn legal-status Critical Current

Links

JP2000535362A 1998-03-09 1999-02-24 Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用 Withdrawn JP2002506044A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/037,118 US6004937A (en) 1998-03-09 1998-03-09 Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
US09/037,118 1998-03-09
PCT/US1999/004003 WO1999045949A2 (en) 1998-03-09 1999-02-24 Use of follistatin to modulate gdf-8 and bmp-11

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2009222855A Division JP2010043099A (ja) 1998-03-09 2009-09-28 Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用
JP2010061242A Division JP2010195794A (ja) 1998-03-09 2010-03-17 Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用

Publications (2)

Publication Number Publication Date
JP2002506044A JP2002506044A (ja) 2002-02-26
JP2002506044A5 true JP2002506044A5 (https=) 2006-07-06

Family

ID=21892528

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000535362A Withdrawn JP2002506044A (ja) 1998-03-09 1999-02-24 Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用
JP2009222855A Pending JP2010043099A (ja) 1998-03-09 2009-09-28 Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用
JP2010061242A Pending JP2010195794A (ja) 1998-03-09 2010-03-17 Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009222855A Pending JP2010043099A (ja) 1998-03-09 2009-09-28 Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用
JP2010061242A Pending JP2010195794A (ja) 1998-03-09 2010-03-17 Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用

Country Status (11)

Country Link
US (1) US6004937A (https=)
EP (3) EP1444985A3 (https=)
JP (3) JP2002506044A (https=)
AT (1) ATE256475T1 (https=)
AU (1) AU759838B2 (https=)
CA (1) CA2322716C (https=)
DE (1) DE69913665T2 (https=)
DK (1) DK1061940T3 (https=)
ES (1) ES2212533T3 (https=)
PT (1) PT1061940E (https=)
WO (1) WO1999045949A2 (https=)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
WO1993009229A1 (en) 1991-11-04 1993-05-13 Genetics Institute, Inc. Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US7566768B1 (en) 1995-10-26 2009-07-28 The Johns Hopkins University School Of Medicine Promyostatin peptides and methods of using same
WO1994026892A1 (en) * 1993-05-12 1994-11-24 Genetics Institute, Inc. Bmp-11 compositions
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
AU689184B2 (en) 1993-12-07 1998-03-26 Genetics Institute, Llc BMP-12, BMP-13 and tendon-inducing compositions thereof
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6004937A (en) * 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
WO2001009368A1 (en) * 1999-07-30 2001-02-08 The General Hospital Corporation Follistatin antagonists
DK1223990T3 (da) 1999-10-15 2004-11-29 Inst Genetics Llc Formuleringer af hyaluronsyre til tilförsel af osteogene proteiner
TW200526779A (en) * 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
EP1790726B1 (en) * 2001-02-08 2013-07-03 Wyeth LLC Modified and stabilized GDF propeptides and uses thereof
KR100420798B1 (ko) * 2001-02-10 2004-03-02 (주)알에이싸이언스 펩타이드 벡터
US7226587B2 (en) 2001-06-01 2007-06-05 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
US20030103959A1 (en) * 2001-06-22 2003-06-05 Hughes Paul E. Methods of providing neuroprotection and/or neurorestoration via the neural activin type IIB receptor
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US6798160B2 (en) * 2001-11-02 2004-09-28 Honda Giken Kogyo Kabushiki Kaisha Electric working machine
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
GB2385052A (en) * 2002-02-05 2003-08-13 Leuven K U Res & Dev Treatment of spondyloarthropathies
EP1572909A4 (en) * 2002-02-21 2007-06-06 Wyeth Corp PROTEIN CONTAINING A DOMAINE OF FOLLISTATIN
BR0307871A (pt) 2002-02-21 2005-04-12 Wyeth Corp Proteìnas contendo domìnio de folistatina
MXPA05002968A (es) * 2002-09-16 2005-09-08 Univ Johns Hopkins Activacion de miostatina por metaloproteasa, y metodos de modular la actividad de miostatina.
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US20050192225A1 (en) * 2002-12-18 2005-09-01 Bowen Richard L. Methods for treating Parkinson's disease
RU2322261C2 (ru) * 2003-06-02 2008-04-20 Уайт Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
JP5392981B2 (ja) 2003-09-12 2014-01-22 ワイス・エルエルシー 骨形成蛋白の送達のための注入可能なリン酸カルシウム固体ロッドおよびペースト
EP1699820A2 (en) * 2003-12-31 2006-09-13 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
JP4688483B2 (ja) * 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
AU2005272646A1 (en) * 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
CA2594276A1 (en) 2004-12-30 2006-07-13 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
WO2006081379A1 (en) * 2005-01-26 2006-08-03 Wyeth Use of sfrps as markers of bmp activity
NZ538097A (en) * 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
JP2008537777A (ja) * 2005-03-23 2008-09-25 ワイス Ｇｄｆ−８調節剤に対する免疫応答の検出
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
US8236751B2 (en) * 2007-03-07 2012-08-07 The Johns Hopkins University Methods of increasing muscle mass using follistatin-like related gene (FLRG)
CA2685540C (en) 2007-08-03 2018-10-16 Graham Michael Wynne Drug combinations for the treatment of duchenne muscular dystrophy
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CN102131822A (zh) 2008-06-26 2011-07-20 阿塞勒隆制药公司 进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US9873739B2 (en) 2012-08-01 2018-01-23 Ikaika Therapeutics, Llc Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (LTBP4)
EA202090632A1 (ru) 2014-06-04 2020-07-31 Акселерон Фарма Инк. Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
EP3274457A4 (en) 2015-03-26 2018-08-08 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
WO2019046903A1 (en) * 2017-09-08 2019-03-14 Baker Heart and Diabetes Institute THERAPEUTIC METHOD FOR INCREASING MUSCLE MASS IN A SUBJECT
WO2020132647A1 (en) 2018-12-21 2020-06-25 Northwestern University Use of annexins in preventing and treating muscle membrane injury
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041538A (en) * 1987-08-28 1991-08-20 The Salk Institute For Biological Studies Mammalian follistatin
US5171579A (en) * 1991-10-11 1992-12-15 Genetics Institute, Inc. Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
DK0690873T3 (da) * 1993-03-19 2003-09-29 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-8
WO1994026892A1 (en) * 1993-05-12 1994-11-24 Genetics Institute, Inc. Bmp-11 compositions
JPH09503673A (ja) * 1993-10-14 1997-04-15 プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ ニューロン細胞の誘導および維持法
US5545616A (en) * 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
US6281332B1 (en) * 1994-12-02 2001-08-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
GB2306481A (en) * 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
US6004937A (en) * 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]

Similar Documents

Publication Publication Date Title
JP2002506044A5 (https=)
Carlstedt et al. Functional recovery in primates with brachial plexus injury after spinal cord implantation of avulsed ventral roots.
Barbeau et al. Enhancement of locomotor recovery following spinal cord injury
Spaić et al. Microsurgical DREZotomy for pain of spinal cord and Cauda equina injury origin: clinical characteristics of pain and implications for surgery in a series of 26 patients
EP3746126B1 (en) Methods and compositions for treating sleep apnea or simple snoring
ATE256475T1 (de) Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten
Dietz et al. Recovery from spinal cord injury—underlying mechanisms and efficacy of rehabilitation
Sood et al. Treatment of painful neuromas of the hand and wrist by relocation into the pronator quadratus muscle
ATE217197T1 (de) Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa
Butler et al. Bupivacaine and Kaltostat reduces post-operative donor site pain
Sériès et al. Corticomotor control of the genioglossus in awake OSAS patients: a transcranial magnetic stimulation study
Carlstedt Approaches permitting and enhancing motoneuron regeneration after spinal cord, ventral root, plexus and peripheral nerve injuries
Saboisky et al. Potential therapeutic targets in obstructive sleep apnoea
Pion et al. Transcutaneous and direct electrical stimulation of mouse sciatic nerve accelerates functional recovery after nerve transection and immediate repair
Dimitrijevic et al. Motor control physiology below spinal cord injury: residual volitional control of motor units in paretic and paralyzed muscles
Vazquez et al. The effects of sensory stimulation on REM sleep duration
RU2120289C1 (ru) Способ лечения больных с неврологическими проявлениями остеохондроза позвоночника
SE1550338A1 (en) A composition for use in the treatment of intervertebral misalignment
Hayakawa et al. Nerve growth factor prevention of aged-rat sympathetic neuron injury by cisplatin, vincristine and taxol–in vitro explant study
Sulaiman et al. Congenital fibre type disproportion with unusual clinico-pathologic manifestations.
AU6418296A (en) Aromatic acid diamides with antigastrin activity, a method for their preparation and their pharmaceutical use
Bruetsch et al. THE PARKINSONIAN SYNDROME DUE TO TRAUMA*: A Clinico-Anatomical Study of A Case
Jawa et al. Pathogenesis and classification of elbow stiffness
Ray et al. Effect of Moringa oleifera root extract on penicillin-induced epileptic rats
JP2009504636A (ja) 血漿または血清を含む神経損傷治療用の医薬組成物